Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer : Update Bulletin # 2 [March 2019]

Product Code:
Publication Date:
March 2019

This edition presents key opinion leader (KOL) views on recent developments in the colorectal cancer (CRC) market. Topics covered include: Gritstone Oncology announcing that the FDA had granted Fast Track designation to GRANITE-001, its personalised immunotherapy containing tumour-specific neoantigens (TSNA), for the treatment of CRC; Isofol Medical reporting that the first patient had been enrolled in the pivotal Phase III AGENT study evaluating its intravenously administered folate-based compound arfolitixorin as a first-line treatment for metastatic CRC (mCRC); Noxxon Pharma announcing that it would present updated safety and survival data for its CXCL12 chemokine inhibitor olaptesed pegol (NOX-A12), from the Phase I KEYNOTE-559 trial, at the American Association for Cancer Research (AACR) Annual Meeting in April 2019 (AACR19).

Business Questions:

  • Is combining the tumour-specific neoantigen-based immunotherapy GRANITE-001 with the immune checkpoint inhibitors Opdivo and Yervoy regarded as a logical approach for treating CRC?
  • Do KOLs foresee any safety issues arising from the use of GRANITE-001 in combination with Opdivo/Yervoy?
  • How do KOLs rate the chances of GRANITE-001 plus Opdivo/Yervoy combination reaching the oncology market?
  • Will the shift in practice towards administering 5-fluorouracil by infusion, rather than by a bolus dose, impact the need for folate-based drugs such as arfolitixorin and leucovorin for mCRC treatment?
  • Do KOLs expect arfolitixorin to demonstrate superiority over leucovorin in the Phase III AGENT trial?
  • Can arfolitixorin successfully reach the market for mCRC? What do KOLs say?
  • Is the combination of the CXCL12 chemokine inhibitor olaptesed pegol with the immune checkpoint inhibitor Keytruda viewed as a rational design for tumour treatment in patients with cancer?
  • How do KOLs view the early data for olaptesed pegol/Keytruda? Is it possible to predict whether the combination will reach the market as an anti-tumour therapy on the basis of these data?


All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved